Drug Pipeline

Camonsertib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
3
Recruiting
4
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-04 NCT07156227
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for…		 Recruitment opened
Active Studies by Phase
Phase 2
2
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05601440 Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2… Breast Cancer Recruiting
NCT04589845 Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You… Solid Tumors Active, Not Recruiting
Phase 1
NCT04855656 Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With… Advanced Solid Tumor Recruiting
NCT07156227 Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for… Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Recruiting
Sponsors Running Camonsertib Trials
Hoffmann-La Roche (1) Debiopharm International SA (1) Canadian Cancer Trials Group (1) National Cancer Institute (NCI) (1)
Disease Areas
Breast Cancer (1) Head & Neck Cancer (1)
Get alerts when Camonsertib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free